Abstract:

In 2023, significant advancements were made in the treatment of hormone receptor positive (HR+ )/human epidermal growth factor receptor 2 negative (HER-2-) breast cancer. This article reviews key clinical studies on breast cancer in 2023, with a particular focus on the progress in neoadjuvant and adjuvant therapeutic strategies, as well as the frontline application of CDK4/6 inhibitors in the treatment of advanced breast cancer. Studies have shown that neoadjuvant immunotherapy combined with chemotherapy can significantly improve the pathological complete response rate in high-risk HR+ /HER2- breast cancer patients. In terms of adjuvant therapy, CDK4/6 inhibitors have demonstrated significant improvements in invasive disease-free survival. For advanced breast cancer, the combination of CDK4/6 inhibitors with endocrine therapy has become the new standard of care. The article also discusses treatment strategies for patients who have failed CDK4/6 inhibitor therapy, including the use of novel antibody-drug conjugates, PI3K inhibitors, AKT inhibitors and new oral selective estrogen receptor degraders. In summary, the research findings have provided more treatment options for patients with HR+ /HER2- breast cancer, with the potential to further enhance their quality of life and overall survival. Future research will continue to optimize treatment strategies to achieve more precise and effective personalized therapy.

Key words: Breast neoplasms, Hormone receptor, Clinical study, Cyclin-dependent kinase